Phil Newman

About

Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity, a media and finance business focused on bringing together innovators and investors to commercialise the companies that will form the Longevity economy.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
131 POSTS

/

0 COMMENTS

Articles

A year in Longevity: investment perspectives

New funds, switching focus to Longevity, Silicon Valley blue-bloods and preparing for IPO. Over the past year, we’ve had the pleasure of speaking with some...

Investing in the age of Longevity: Investment panel

The Longevity Week: Master Investor Masterclass The Investment Panel investigates demonstrated Longevity growth, name-checking some hot areas for investment, seeing how Longevity-ready institutional investors are...

Investing in the age of Longevity: Science panel

The Longevity Week: Master Investor Masterclass It was the Longevity Forum's Longevity Week this week and this Science Panel, supported by Master Investor, benchmarks current...

Neurotech2020: It’s a brave new world

It's an online conference, but not as you know it. Say goodbye to Zoom fatigue and hello to Neurotech2020. Understanding the brain, consciousness and thought...

Longevity big-hitters join our current investment round

Some news of our own: Key investors join the First Longevity funding round. Among those participating in this second stage funding for First Longevity are...

Journalism Matters Week: We’re doing our bit!

2020 has been an incredible year. For journalists, and a huge number of other professions, it has been one of the biggest periods of...

Startup Showcase: Rejuvenate Biomed: What do you think?

Rejuvenate Biomed are ready to take their first Longevity therapy into clinical trials: Invest, buy, or both? It's time to have your say on...

Exclusive video interview with Dave Asprey

We talk supplementation, neurotech, mitochondrial dysfunction, clinical scale-ups, COVID and CGM with Longevity legend: Dave Asprey Ahead of Revolution Against Aging and Death conference, which...

Startup Showcase: Jinfiniti: What do you think?

Comprehensive biomarker tech: Invest, buy, or both? It's time to have your say on Jinfiniti. We like what Jinfiniti are doing; but that's just our...